Cassian Yee, M.D.

Peer-Reviewed Articles

1. Singh S, Long JP, Tchakarov A, Dong Y, Yee C, Lin JS. Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis. JCI Insight. e-Pub 2022. PMID: 36472921.
2. Li H, Xiao Y, Li Q, Yao J, Yuan X, Zhang Y, Yin X, Saito Y, Fan H, Li P, Kuo WL, Halpin A, Gibbons DL, Yagita H, Zhao Z, Pang D, Ren G, Yee C, Lee JJ, Yu D. The allergy mediator histamine confers resistanceto immunotherapy in cancer patients via activationof the macrophage histamine receptor H1. Cancer Cell, 2022. e-Pub 2021. PMID: 34822775.
3. Pan K, Chiu Y, Huang E, Chen M, Wang J, Lai I, Singh S, Shaw RM, MacCoss MJ, Yee C*. Mass spectrometric identification of immunogenic SARS-CoV-2 epitopes and cognate TCRs. Proc Natl Acad Sci U S A 118(46), 2021. PMID: 34725257.
4. Li F, Deng L, Jackson KR, Talukder AH, Katailiha AS, Bradley SD, Zou Q, Chen C, Huo C, Chiu Y, Stair M, Feng W, Bagaev A, Kotlov N, Svekolkin V, Ataullakhanov R, Miheecheva N, Frenkel F, Wang Y, Zhang M, Hawke D, Han L, Zhou S, Zhang Y, Wang Z, Decker WK, Sonnemann HM, Roszik J, Forget MA, Davies MA, Bernatchez C, Yee C, Bassett R, Hwu P, Du X, Lizee G. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 9(7), 2021. PMID: 34244308.
5. Pan K, Chiu Y, Chen M, Wang J, Lai I, Singh S, Shaw R, Yee C*. In Silico Defined SARS-CoV2 Epitopes May Not Predict Immunogenicity to COVID19. bioRxiv, 2021. e-Pub 2021. PMID: 34268504.
6. Pan K, Chiu Y, Huang E, Chen M, Wang J, Lai I, Singh S, Shaw R, MacCoss M, Yee C*. Immunogenic SARS-CoV2 Epitopes Defined by Mass Spectrometry. bioRxiv, 2021. e-Pub 2021. PMID: 34312620.
7. Mueller-Schoell A, Puebla-Osorio N, Michelet R, Green MR, Künkele A, Huisinga W, Strati P, Chasen B, Neelapu SS, Yee C*, Kloft C. Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers (Basel) 13(11), 2021. e-Pub 2021. PMID: 34205020.
8. Hasan F, Chiu Y, Shaw RM, Wang J, Yee C*. Hypoxia acts as an environmental cue for the human tissue resident memory T cell differentiation program. JCI Insight 6(10), 2021. e-Pub 2021. PMID: 34027895.
9. Kohli K, Yao L, Nowicki TS, Zhang S, Black RG, Schroeder BA, Farrar EA, Cao J, Sloan H, Stief D, Cranmer LD, Wagner MJ, Hawkins DS, Pillarisetty VG, Ribas A, Campbell J, Pierce RH, Kim EY, Jones RL, Riddell SR, Yee C, Pollack SM. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy. J Immunother Cancer 9(5), 2021. PMID: 33963013.
10. Abdelrahim M, Mamlouk O, Lin H, Lin J, Page V, Abdel-Wahab N, Swan J, Selamet U, Yee C, Diab A, Suki W, Abudayyeh A. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. Oncoimmunology 10(1):1927313, 2021. e-Pub 2021. PMID: 34104543.
11. Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelwahab N, Abdelrahim M, Diab A, Yee C*, Abudayyeh A. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology 10(1):1877415, 2021. e-Pub 2021. PMID: 33643693.
12. Hou J, Wang Y, Shi L, Chen Y, Xu C, Saeedi A, Pan K, Bohat R, Egan NA, McKenzie JA, Mbofung RM, Williams LJ, Yang Z, Sun M, Liang X, Rodon Ahnert J, Varadarajan N, Yee C, Chen Y, Hwu P, Peng W. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. J Immunother Cancer 9(2), 2021. PMID: 33589527.
13. Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, Yee C*, Lizée G. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun 11(1):5332, 2020. e-Pub 2020. PMID: 33087697.
14. Lin JS, Wang DY, Mamlouk O, Glass WF, Abdelrahim M, Yee C, Abudayyeh A. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab. J Immunother Cancer 8(2), 2020. PMID: 33020246.
15. Kim S, Cho H, Hong SO, Oh SJ, Lee HJ, Cho E, Woo SR, Song JS, Chung JY, Son SW, Yoon SM, Jeon YM, Jeon S, Yee C, Lee KM, Hewitt SM, Kim JH, Song KH, Kim TW. LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells. Autophagy:1-20. e-Pub 2020. PMID: 32762616.
16. Ma Y, Li J, Wang H, Chiu Y, Kingsley CV, Fry D, Delaney SN, Wei SC, Zhang J, Maitra A, Yee C*. Combination of PD1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. Gastroenterology 159(1):306-319.e12, 2020. e-Pub 2020. PMID: 32179091.
17. An X, Martinez-Paniagua M, Rezvan A, Fathi M, Singh S, Biswas S, Pourpak M, Yee C, Liu X, Varadarajan N. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. bioRxiv, 2020. e-Pub 2020. PMID: 32743568.
18. Wang J, Hasan F, Frey AC, Li HS, Park J, Pan K, Haymaker C, Bernatchez C, Lee DA, Watowich SS, Yee C*. Histone deacetylase inhibitors and IL21 cooperate to reprogram human effector CD8+ T cells to memory T cells. Cancer Immunol Res 8(6):794-805, 2020. e-Pub 2020. PMID: 32213626.
19. Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, Sakellariou-Thompson DA, Chen E, Reddy SM, Spencer CN, Wiesnoski D, Little LD, Gumbs C, Cooper ZA, Burton EM, Hwu P, Davies MA, Zhang J, Bernatchez C, Navin N, Sharma P, Allison JP, Wargo JA, Yee C, Tetzlaff MT, Hwu WJ, Lazar AJ, Futreal PA. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun 11(1):1839, 2020. e-Pub 2020. PMID: 32296058.
20. Schroeder BA, Black RG, Spadinger S, Zhang S, Kohli K, Cao J, Mantilla JG, Conrad EU, Riddell SR, Jones RL, Yee C, Pollack SM. Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy. J Immunother Cancer 8(1), 2020. PMID: 32269142.
21. Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, Ghosh S, Mottok A, Nastoupil L, Neelapu SS, Weigert O, Inghirami G, Baselga J, Younes A, Yee C, Dogan A, Scheinberg DA, Roeder RG, Melnick AM, Green MR. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov 10(3):440-459, 2020. e-Pub 2020. PMID: 31915197.
22. Song KH, Oh SJ, Kim S, Cho H, Lee HJ, Song JS, Chung JY, Cho E, Lee J, Jeon S, Yee C, Lee KM, Hewitt SM, Kim JH, Woo SR, Kim TW. HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors. Nat Commun 11(1):562, 2020. e-Pub 2020. PMID: 31992715.
23. Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, Tummala S, Woodman K, Abdel-Wahab N, Diab A. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7(1):319, 2019. e-Pub 2019. PMID: 31753014.
24. Chu F, Li HS, Liu X, Cao J, Ma W, Ma Y, Weng J, Zhu Z, Cheng X, Wang Z, Liu J, Jiang ZY, Luong AU, Peng W, Wang J, Balakrishnan K, Yee C, Dong C, Davis RE, Watowich SS, Neelapu SS. CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity. Leukemia 33(11):2640-2653, 2019. e-Pub 2019. PMID: 31028278.
25. Zhang S, Kohli K, Black RG, Yao L, Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee C, Pierce RH, Riddell SR, Jones RL, Pollack SM. Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. Cancer Immunol Res 7(8):1237-1243, 2019. e-Pub 2019. PMID: 31171504.
26. Zhang, Shihong ; Kohli, Karan ; Black, R Graeme ; Yao, Lu ; Spadinger, Sydney M ; He, Qianchuan ; Pillarisetty, Venu G ; Cranmer, Lee D ; Van Tine, Brian A ; Yee, Cassian ; Pierce, Robert H ; Riddell, Stanley R ; Jones, Robin L ; Pollack, Seth M; Zhang, Shihong (correspondence author) ; Zhang, Shihong (record owner. Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. Cancer immunology research 7(8):1237-1243, 2019.
27. Kim TJ, Park G, Kim J, Lim SA, Kim J, Im K, Shin MH, Fu YX, Del Rio ML, Rodriguez-Barbosa JI, Yee C, Suh KS, Kim SJ, Ha SJ, Lee KM. CD160 serves as a negative regulator of NKT cells in acute hepatic injury. Nat Commun 10(1):3258, 2019. e-Pub 2019. PMID: 31332204.
28. Fan J, Liang H, Ji X, Wang S, Xue J, Li D, Peng H, Qin C, Yee C*, Shao Y. CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques. Nat Commun 10(1):2257, 2019. e-Pub 2019. PMID: 31113957.
29. Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31096717.
30. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 7(1):107, 2019. e-Pub 2019. PMID: 30995944.
31. Johnson, Daniel H ; Zobniw, Chrystia M ; Trinh, Van A ; Ma, Junsheng ; Bassett, Roland L ; Abdel-Wahab, Noha ; Anderson, Jaime ; Davis, Jennifer E ; Joseph, Jocelyn ; Uemura, Marc ; Noman, Ali ; Abu-Sbeih, Hamzah ; Yee, Cassian ; Amaria, Rodabe ; Patel, Sapna ; Tawbi, Hussein ; Glitza, Isabella C ; Davies, Michael A ; Wong, Michael K ; Woodman, Scott ; Hwu, Wen-Jen ; Hwu, Patrick ; Wang, Yinghong ; Diab, Adi. Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis (Journal for ImmunoTherapy of Cancer (2018) 6 (103) DOI: 10.1186/s40425-018-0412-0). Journal for immunotherapy of cancer 7(1):107, 2019.
32. Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 7(1):2, 2019. e-Pub 2019. PMID: 30612580.
33. Choi HY, Yang GM, Dayem AA, Saha SK, Kim K, Yoo Y, Hong K, Kim JH, Yee C, Lee KM, Cho SG. Hydrodynamic shear stress promotes epithelial-mesenchymal transition by downregulating ERK and GSK3β activities. Breast Cancer Res 21(1):6, 2019. e-Pub 2019. PMID: 30651129.
34. Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A 116(5):1692-1697, 2019. e-Pub 2019. PMID: 30635425.
35. Ott PA, Dotti G, Yee C, Goff SL. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines. Am Soc Clin Oncol Educ Book 39:e70-e78, 2019. e-Pub 2019. PMID: 31099621.
36. Lim SA, Kim J, Jeon S, Shin MH, Kwon J, Kim TJ, Im K, Han Y, Kwon W, Kim SW, Yee C, Kim SJ, Jang JY, Lee KM. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol 10:496, 2019. e-Pub 2019. PMID: 31024520.
37. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 6(1):103, 2018. e-Pub 2018. PMID: 30305177.
38. Chua CYX, Jain P, Susnjar A, Rhudy J, Folci M, Ballerini A, Gilbert A, Singh S, Bruno G, Filgueira CS, Yee C, Butler EB, Grattoni A. Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer. J Control Release 285:23-34, 2018. e-Pub 2018. PMID: 30008369.
39. Paulson, K G ; Voillet, V ; Mcafee, M S ; Hunter, D S ; Wagener, F D ; Perdicchio, M ; Valente, W J ; Koelle, S J ; Church, C D ; Vandeven, N ; Thomas, H ; Colunga, A G ; Iyer, J G ; Yee, C ; Kulikauskas, R ; Koelle, D M ; Pierce, R H ; Bielas, J H ; Greenberg, P D ; Bhatia, S ; Gottardo, R ; Nghiem, P ; Chapuis, A G; Paulson, K G (correspondence author) ; Paulson, K G (record owner). Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nature communication 1(9):3868, 2018.
40. Song KH, Kim JH, Lee YH, Bae HC, Lee HJ, Woo SR, Oh SJ, Lee KM, Yee C, Kim BW, Cho H, Chung EJ, Chung JY, Hewitt SM, Chung TW, Ha KT, Bae YK, Mao CP, Yang A, Wu TC, Kim TW. Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. J Clin Invest. e-Pub 2018. PMID: 30124467.
41. Fan J, Liang H, Shen T, Wang S, Ji X, Yee C, Lu F, Shao Y. Early Env-specific CTLs effectively suppress viral replication in SHIV controller macaques. Cell Immunol. e-Pub 2018. PMID: 29773224.
42. Zhang H, Li Y, Liu X, Liang Z, Yan M, Liu Q, Chen A, Bao Y, Zhou C, Li S, Yee C, Li Y. ImmTAC/Anti-PD-1 Combination to Enhance Killing of Cancer cells by Reversing Treg-mediated Immunosuppression. Immunology. e-Pub 2018. PMID: 29791021.
43. Yee C*. Adoptive T cell therapy: points to consider. Curr Opin Immunol 51:197-203, 2018. e-Pub 2018. PMID: 29730057.
44. Mendt M, Kamerkar S, Sugimoto H, McAndrews KM, Wu CC, Gagea M, Yang S, Blanko EVR, Peng Q, Ma X, Marszalek JR, Maitra A, Yee C, Rezvani K, Shpall E, LeBleu VS, Kalluri R. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight 3(8). e-Pub 2018. PMID: 29669940.
45. Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, Wistuba II, Katz M, Varadhachary G, Park Y, Hicks J, Chinnaiyan A, Scampavia L, Spicer T, Gerhardinger C, Maitra A, Tuveson D, Rinn J, Lizee G, Yee C, Levine AJ. Dynamic changes during the treatment of pancreatic cancer. Oncotarget 9(19):14764-14790, 2018. e-Pub 2018. PMID: 29599906.
46. Oh SJ, Cho H, Kim S, Noh KH, Song KH, Lee HJ, Woo SR, Kim S, Choi CH, Chung JY, Hewitt SM, Kim JH, Baek S, Lee KM, Yee C, Park HC, Kim TW. Targeting Cyclin D-CDK4/6 sensitizes immune-refractory cancer by blocking the SCP3-NANOG axis. Cancer Res. e-Pub 2018. PMID: 29437706.
47. Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3(1):e000283, 2018. e-Pub 2018. PMID: 29387478.
48. Park J, Talukder AH, Lim SA, Kim K, Pan K, Melendez B, Bradley SD, Jackson KR, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, Hwu P, Lee KM, Roszik J, Lizée G, Yee C*. SLC45A2: A melanoma antigen with high tumor selectivity and reduced potential for autoimmune toxicity. Cancer Immunol Res 5(8):618-629, 2017. e-Pub 2017. PMID: 28630054.
49. Song KH, Choi CH, Lee HJ, Oh SJ, Woo SR, Hong SO, Noh KH, Cho H, Chung EJ, Kim JH, Chung JY, Hewitt SM, Baek S, Lee KM, Yee C, Son M, Mao CP, Wu TC, Kim TW. HDAC1 upregulation by NANOG promotes multidrug resistance and a stem-like phenotype in immune edited tumor cells. Cancer Res. e-Pub 2017. PMID: 28716899.
50. Yee C*, Lizee GA. Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy. Cancer J 23(2):144-148, 2017. PMID: 28410303.
51. Yee C*. From the Guest Editor. Cancer J 23(2):95-96, 2017. PMID: 28410295.
52. Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee C*. Tracking the fate and origin of clinically relevant adoptively transferred CD8+ T cells in vivo. Sci Immunol 2(8), 2017. e-Pub 2017. PMID: 28367538.
53. Roszik J, Wang WL, Livingston JA, Roland CL, Ravi V, Yee C, Hwu P, Futreal A, Lazar AJ, Patel SR, Conley AP. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res 7:11, 2017. e-Pub 2017. PMID: 28630682.
54. Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med 14(1):313, 2016. e-Pub 2016. PMID: 27846884.
55. Chapuis AG, Lee SM, Thompson JA, Roberts IM, Margolin KA, Bhatia S, Sloan HL, Lai I, Wagener F, Shibuya K, Cao J, Wolchok JD, Greenberg PD, Yee C*. Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J Exp Med 213(7):1133-9, 2016. e-Pub 2016. PMID: 27242164.
56. Chapuis AG, Roberts IM, Thompson JA, Margolin KA, Bhatia S, Lee SM, Sloan HL, Lai IP, Farrar EA, Wagener F, Shibuya KC, Cao J, Wolchok JD, Greenberg PD, Yee C*. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J Clin Oncol. e-Pub 2016. PMID: 27269940.
57. Ju B, Li D, Ji X, Liu J, Peng H, Wang S, Liu Y, Hao Y, Yee C, Liang H, Shao Y. Interleukin-21 administration leads to enhanced antigen-specific T cell responses and natural killer cells in HIV-1 vaccinated mice. Cell Immunol 303:55-65, 2016. e-Pub 2016. PMID: 27062692.
58. Yee C*, Lizee G, Schueneman AJ. Endogenous T-Cell Therapy: Clinical Experience. Cancer J 21(6):492-500, 2015. PMID: 26588682.
59. Noh KH, Kim SH, Kim JH, Song KH, Lee YH, Kang TH, Han HD, Sood AK, Ng J, Kim K, Sonn CH, Kumar V, *Yee C, *Lee KM, *Kim TW (*co-corresponding authors). API5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Res 74(13):3556-66, 2014. e-Pub 2014. PMID: 24769442.
60. Hwang SW, Park G, Edwards C, Corbin EA, Kang SK, Cheng H, Song JK, Kim JH, Yu S, Ng J, Lee JE, Kim J, Yee C, Bhaduri B, Su Y, Omennetto FG, Huang Y, Bashir R, Goddard L, Popescu G, Lee KM, Rogers JA. Dissolution chemistry and biocompatibility of single-crystalline silicon nanomembranes and associated materials for transient electronics. ACS Nano 8(6):5843-51, 2014. e-Pub 2014. PMID: 24684516.
61. Park G, Chung HJ, Kim K, Lim SA, Kim J, Kim YS, Liu Y, Yeo WH, Kim RH, Kim SS, Kim JS, Jung YH, Kim TI, Yee C, Rogers JA, Lee KM. Immunologic and Tissue Biocompatibility of Flexible/Stretchable Electronics and Optoelectronics. Adv Healthc Mater 3(4):515-25, 2014. e-Pub 2013. PMID: 23996980.
62. Lee JE, Lim SA, Kim TJ, Kim K, Ng J, Kim YH, Jang IJ, Oh SB, Lee JC, Yee C, Kumar V, Lee KM. NKG2D ligation relieves 2B4-mediated NK-cell self-tolerance in mice. Eur J Immunol. e-Pub 2014. PMID: 24610736.
63. Yee C*. The use of endogenous T cells for adoptive transfer. Immunol Rev 257(1):250-63, 2014. PMID: 24329802.
64. Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, Lai I, Roberts IM, Sloan HL, Bhatia S, Shibuya KC, Gooley T, Desmarais C, Koelle DM, *Yee C*, *Nghiem P (*co-corresponding authors). Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res 2(1):27-36, 2014. PMID: 24432305.
65. Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci 15(1):927-43, 2014. e-Pub 2014. PMID: 24434638.
66. Shibuya KC, Goel VK, Xiong W, Sham JG, Pollack SM, Leahy AM, Whiting SH, Yeh MM, Yee C, Riddell SR, Pillarisetty VG. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One 9(5):e96565, 2014. e-Pub 2014. PMID: 24794217.
67. Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C*. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer 2(1):36, 2014. e-Pub 2014. PMID: 25317334.
68. Kim TJ, Kim M, Kim HM, Lim SA, Kim EO, Kim K, Song KH, Kim J, Kumar V, Yee C, Doh J, Lee KM. Homotypic NK cell-to-cell communication controls cytokine responsiveness of innate immune NK cells. Sci Rep 4:7157, 2014. e-Pub 2014. PMID: 25475707.
69. Yee C*. Adoptive T-cell therapy for cancer: boutique therapy or treatment modality?. Clin Cancer Res 19(17):4550-2, 2013. e-Pub 2013. PMID: 23922301.
70. Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE. HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol 191(4):1567-77, 2013. e-Pub 2013. PMID: 23851683.
71. Stroncek, D. F., Melief, C. J. M., Castiello, L., Cesano, A., Cheever, M. A., Civini, S., Comin-Anduix, B., Gajewski, T. F., Greenberg, P. D., Kalinski, P., Kaufman, H. L., Kershaw, M. H., Khleif, S. N., Marincola, F., Merritt, W., Munn, D. H., Powell, D. J., Restifo, N. P., Rosenberg, S. A., Puri, R. K. & 5 others. Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting. Journal for Immunotherapy of Cancer, 2013.
72. Lim SA, Kim TJ, Lee JE, Sonn CH, Kim K, Kim J, Choi JG, Choi IK, Yun CO, Kim JH, Yee C, Kumar V, Lee KM. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. Cancer Res 73(8):2598-607, 2013. e-Pub 2013. PMID: 23580577.
73. Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, Duerkopp N, Roberts IM, Pogosov GL, Ho WY, Ochsenreither S, Wölfl M, Bar M, Radich JP, Yee C*, Greenberg PD (co-corresponding athors: CY and PDG). Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 5(174):174ra27, 2013. PMID: 23447018.
74. Seung-Hyun Jun, Kwanghee Kim, Hyo Jin An, Byoung Chan Kim, Chung Hee Sonn, Miju Kim, Junsang Doh, Cassian Yee*, Kyung-Mi Lee, Jungbae Kim. Ethanol-Dispersed Polymer Nanofibers as a Highly Selective Cell Isolation and Release Platform for CD4(+) T Lymphocytes. Advanced Functional Materials 22(21):4448-4455, 2012.
75. Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C*. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 118(18):4564-70, 2012. e-Pub 2012. PMID: 22359263.
76. Kim K, An HJ, Jun SH, Kim TJ, Lim SA, Park G, Na HB, Park YI, Hyeon T, Yee C, Bluestone JA, Kim J, Lee KM. Single step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers. Nano Lett 12(8):4018-24, 2012. e-Pub 2012. PMID: 22784189.
77. Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, Li Y, Yee C*. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 109(12):4592-7, 2012. e-Pub 2012. PMID: 22393002.
78. Chou J, Voong LN, Mortales CL, Towlerton AM, Pollack SM, Chen X, Yee C, Robbins PF, Warren EH. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother 35(2):131-41, 2012. PMID: 22306901.
79. Lee SM, Yee C. Another LAP in the race. Cancer Discov 2(2):107-9, 2012. PMID: 22585852.
80. Robins H, Desmarais C, Matthis J, Livingston R, Andriesen J, Reijonen H, Carlson C, Nepom G, Yee C, Cerosaletti K. Ultra-sensitive detection of rare T cell clones. J Immunol Methods 375(1-2):14-9, 2012. e-Pub 2011. PMID: 21945395.
81. Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C*. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One 7(2):e32165, 2012. e-Pub 2012. PMID: 22384167.
82. Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase K, Jing L, Marshak JO, Dong L, Carter J, Lai I, Farrar E, Byrd D, Galloway D, Yee C, Koelle DM, Nghiem P. Merkel cell polyomavirus-specific CD8 and CD4 T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res 17(21):6671-80, 2011. e-Pub 2011. PMID: 21908576.
83. Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA, Chin L, Yee C, Fujita M. Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene Ther 18(8):827-34, 2011. e-Pub 2011. PMID: 21390072.
84. Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C*, Immunotherapy Task Force of the NCI Investigational Drug Steering Committee. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 17(7):1664-73, 2011. e-Pub 2011. PMID: 21325070.
85. Pollack SM, Loggers ET, Rodler ET, Yee C*, Jones RL. Immune-based therapies for sarcoma. Sarcoma 2011:438940, 2011. PMID: 21331153.
86. Hanaoka N, Jabri B, Dai Z, Ciszewski C, Stevens AM, Yee C, Nakakuma H, Spies T, Groh V. NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J Immunol 185(10):5732-42, 2010. e-Pub 2010. PMID: 20926796.
87. Abdul-Alim CS, Li Y, Yee C*. Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses. J Immunol 184(11):6514-21, 2010. e-Pub 2010. PMID: 20483791.
88. Yee C*. Adoptive therapy using antigen-specific T-cell clones. Cancer J 14(4):367-73, 2010.
89. Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee C*. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One 4(3):e4749, 2009. e-Pub 2009. PMID: 19270751.
90. Shah KV, Chien AJ, Yee C, Moon RT. CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J Invest Dermatol 128(12):2870-9, 2008. e-Pub 2008. PMID: 18563180.
91. Gunn J, Wallen H, Veiseh O, Sun C, Fang C, Cao J, Yee C, Zhang M. A multimodal targeting nanoparticle for selectively labeling T cells. Small 4(6):712-5, 2008. PMID: 18528851.
92. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C*. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358(25):2698-703, 2008. PMID: 18565862.
93. Li Y, Yee C*. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111(1):229-35, 2008. e-Pub 2007. PMID: 17921346.
94. von Euw EM, Barrio MM, Furman D, Levy EM, Bianchini M, Peguillet I, Lantz O, Vellice A, Kohan A, Chacón M, Yee C, Wainstok R, Mordoh J. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J Transl Med 6:6, 2008. e-Pub 2008. PMID: 18221542.
95. von Euw EM, Barrio MM, Furman D, Bianchini M, Levy EM, Yee C, Li Y, Wainstok R, Mordoh J. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. J Transl Med 5:19, 2007. e-Pub 2007. PMID: 17448240.
96. Lyons GE, Roszkowski JJ, Man S, Yee C, Kast WM, Nishimura MI. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother 55(9):1142-50, 2006. e-Pub 2005. PMID: 16374636.
97. Yee, Cassian* ; Wallen, Herschel ; Hunder, Naomi ; Thompson, John A ; Byrd, David ; Reilly, J. Zachary ; Hendricks, Deborah ; Kenyon, Karla ; Schirmer, Lisa. Recent advances in the use of antigen-specific T cells for the treatment of cancer. Cancer Therapeutics 1(3):333-342, 2006.
98. Li Y, Bleakley M, Yee C*. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 175(4):2261-9, 2005. PMID: 16081794.
99. Groh V, Li YQ, Cioca D, Hunder NN, Wang W, Riddell SR, Yee C, Spies T. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A 102(18):6461-6, 2005. e-Pub 2005. PMID: 15824323.
100. Yee C*. Adoptive T cell therapy: Addressing challenges in cancer immunotherapy. J Transl Med 3(1):17, 2005. e-Pub 2005. PMID: 15860133.
101. Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res 65(4):1570-6, 2005. PMID: 15735047.
102. Liao X, Li Y, Bonini C, Nair S, Gilboa E, Greenberg PD, Yee C*. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 9(5):757-64, 2004. PMID: 15120337.
103. Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW. Autoreactive T cells in healthy individuals. J Immunol 172(10):5967-72, 2004. PMID: 15128778.
104. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3(5):431-7, 2003. PMID: 12781360.
105. Yee C*. Adoptive T cell therapy--immune monitoring and MHC multimers. Clin Immunol 106(1):5-9, 2003. PMID: 12584044.
106. Yee C*, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99(25):16168-73, 2002. e-Pub 2002. PMID: 12427970.
107. Ho WY, Yee C, Greenberg PD. Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest 110(10):1415-7, 2002. PMID: 12438439.
108. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419(6908):734-8, 2002. PMID: 12384702.
109. Yee C, Greenberg P. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer 2(6):409-19, 2002. PMID: 12189383.
110. Yee C*, Riddell SR, Greenberg PD. In vivo tracking of tumor-specific T cells. Curr Opin Immunol 13(2):141-6, 2001. PMID: 11228405.
111. Yee C*, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med 192(11):1637-44, 2000. PMID: 11104805.
112. Lee PP, Yee C*, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5(6):677-85, 1999. PMID: 10371507.
113. Li L, Yee C*, Beavo JA. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283(5403):848-51, 1999. PMID: 9933169.
114. Yee C*, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162(4):2227-34, 1999. PMID: 9973498.
115. Greenberg PD, Finch RJ, Gavin MA, Kalos M, Lewinsohn DA, Lonergan M, Lord JD, Nelson BH, Ohlén C, Sing AP, Warren EH, Yee C*, Riddell SR. Genetic modification of T-cell clones for therapy of human viral and malignant diseases. Cancer J Sci Am 4 Suppl 1:S100-5, 1998. PMID: 9619278.
116. Yee C*, Riddell SR, Greenberg PD. Prospects for adoptive T cell therapy. Curr Opin Immunol 9(5):702-8, 1997. PMID: 9368780.
117. Yee C*, Gilbert MJ, Riddell SR, Brichard VG, Fefer A, Thompson JA, Boon T, Greenberg PD. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol 157(9):4079-86, 1996. PMID: 8892642.
118. Nagoya S, Greenberg PD, Yee C, Weisser KE, Sugawara H, Widmer MB, Slack J, Dower SK, Lupton SD, Overell RW. Helper T cell-independent proliferation of CD8+ cytotoxic T lymphocytes transduced with an IL-1 receptor retrovirus. J Immunol 153(4):1527-35, 1994. PMID: 8046231.
119. Greenberg PD, Nelson B, Gilbert M, Sing A, Yee C, Jensen M, Riddell SR. Genetic modification of T cell clones to improve the safety and efficacy of adoptive T cell therapy. Ciba Found Symp 187:212-23; discussion 224-8, 1994. PMID: 7796672.
120. Yee C, Sutcliffe S, Messner HA, Minden MD. Interleukin-6 levels in the plasma of patients with lymphoma. Leuk Lymphoma 7(1-2):123-9, 1992. PMID: 1472922.
121. Chang H, Messner HA, Wang XH, Yee C, Addy L, Meharchand J, Minden MD. A human lymphoma cell line with multiple immunoglobulin rearrangements. J Clin Invest 89(3):1014-20, 1992. PMID: 1311715.
122. Yee C|, Messner HA, Minden MD. Regulation of interleukin-6 expression in the lymphoma cell line OCI-LY3. J Cell Physiol 148(3):426-9, 1991. PMID: 1918171.
123. Andersson BS, Luna MA, Yee C, Hui KK, Keating MJ, McCredie KB. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer 65(5):1079-84, 1990. PMID: 2302659.
124. Yee C, Biondi A, Wang XH, Iscove NN, de Sousa J, Aarden LA, Wong GG, Clark SC, Messner HA, Minden MD. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 74(2):798-804, 1989. PMID: 2787680.
125. Minden MD, Yee C, Biondi A, deSousa J. Expression of growth factors in human leukemic cells. Journal Biological chemistry Suppl(12A):123, 1988.
126. Yee C, Shiu RP. Degradation of endothelial basement membrane by human breast cancer cell lines. Cancer Res 46(4 Pt 1):1835-9, 1986. PMID: 3948167.
127. Yee C, Wong HY, Fewer HD, Rogers AG. Two cases of dysphagia due to cervical spine osteophytes successfully treated surgically. Can Med Assoc J 132(7):810-2, 1985. PMID: 3978503.

Other Articles

1. Yee, C Adoptive T-Cell Therapy of Cancer. Hematol Oncol Clin North Am 20(711):33, 2006.

Book Chapters

1. Yee, C.. Immunotherapy with Non-Genetically Modified T Cells. In: Immunotherapy in Translational Cancer Research. Wiley Blackwell, 91-100, 2018.
2. Cassian Yee. Cancer Immunotherapy Principles and Practice, Second Edition. In: Non-engineered T cell Therapy. 2. Demos Medical Publishing, an imprint of Springer Publishing: New York, 2017.
3. Chapuis, Aude G. ; Yee, Cassian. Monitoring antigen-specific responses in clinical trials of cancer immunotherapy. In: Cancer Immunotherapy: Paradigms, Practices and Promise. Springer New York, 425-453, 2013.
4. Yee C. Adoptive therapy using antigen-specific T-cell clones. In: Cancer: Principles & Practice of Oncology: Annual Advances in Oncology. Wolters Kluwer Health Adis (ESP), 367-373, 2012.
5. Pollack, S. M. & Yee, C.. Adoptive immunotherapy of melanoma. In: Innate Immune Regulation and Cancer Immunotherapy. Springer New York, 439-465, 2012.
6. Pollack S & Yee C. Adoptive T Cell Therapy of Solid Tumor Malignancies. In: Innate and adaptive. immune regulation and Cancer immunotherapy. Wang, RF Ed. Springer Press, 2011.
7. Yee C. Tumor Immunotherapy. In: The Molecular Biology of Cancer. 2. Blackwell Publishing: Malden MA, 2011.
8. Yee, C.. Adoptive cellular therapies. In: Cancer Chemotherapy and Biotherapy: Principles and Practice. Wolters Kluwer Health Adis (ESP), 1465-1498, 2011.
9. Yee, C.. Adoptive cellular therapy for the treatment of cancer. In: General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology. Springer Netherlands, 343-361, 2008.
10. Yee C. Adoptive T-cell therapy of cancer. In: Hematol Oncol Clin North Am. 3, 711-33, 2006.
11. Spelengaris S, Yee C. Tumor Immunotherapy. In: The Molecular Biology of Cancer. Blackwell Publishing: Malden MA, 2006.
12. Yee C*, Lee PP. Methods for use of peptide-MHC tetramers in tumor immunology. In: Melanoma techniques and protocols: molecular diagnosis, treatment and monitoring. Nickoloff B. Humana Press, 353-362 (Ch. 20), 2001.